Funder
The Paul G Allen Frontiers Group
National Institutes of Health
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Paul G Allen Family Foundation
Reference10 articles.
1. Phase 3 trial of nemolizumab in patients with prurigo nodularis;Kwatra;N Engl J Med,2023
2. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials;Yosipovitch;Nat Med,2023
3. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis;Simpson;N Engl J Med,2016
4. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2);Wollenberg;Br J Dermatol,2021
5. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus;Silverberg;J Allergy Clin Immunol,2020